AKTARI is proud to be on the leading edge of advancing the treatment of neuro-psychiatric disorders by initiating and participating in Ketamine clinical research trials. It is an exciting time for the field of psychiatry, with ongoing development of safe, rapid and effective treatments for depression and other psychiatric disorders.
There aren’t many clinicians with the training and expertise to conduct this kind of research. Clinical research to evaluate Ketamine’s alleviation of neuropsychiatric symptoms may revolutionize the way doctors and the public think about depression. It could open the door to treatments that are even more effective, including oral pill forms of Ketamine to reduce the dependence upon IV infusion. We may look back one day on Ketamine as the compass that showed us the way towards better solutions, but we’re not quite there yet. Today, Ketamine has no equal in rapidly relieving most types of depression, bipolar syndrome, OCD and PTSD.
“We’re getting closer and closer to having really, truly next-generation treatments that are better and quicker than existing ones.”
Dr. Carlos Zarate, National Institute of Mental Health